Advertisements



Spark Therapeutics shares jump 7.5% after FDA committee backs blindness treatment

Shares of Spark Therapeutics Inc. surged 7.5% premarket Friday, after a U.S. Food and Drugs Administration advisory committee recommended approval of the company's gene therapy treatment for a rare eye disease that causes blindness. .....»»

Category: topSource: marketwatchOct 13th, 2017

Spark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye disease

Spark Therapeutics Inc. shares were halted Thursday as a U.S. Food and Drugs Administration advisory committee meets to review the company's gene therapy treatment for patients with vision loss caused.....»»

Category: topSource: marketwatchOct 12th, 2017

Wall Street Reacts To Spark Therapeutics" $850K Genetic Blindness Treatment

The first gene therap.....»»

Category: blogSource: benzingaJan 3rd, 2018

This Company Has a Possible Cure for Blindness and It’s Charging $425,000 Per Eye

Spark will offer discounts based on whether the drug works A transformative genetic treatment for a rare, inherited form of blindness will come with a price tag of of $425,000 per eye, or $850,000 for both, said Spark Therapeutics Inc.,.....»»

Category: europeSource: fortuneJan 3rd, 2018

Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchDec 19th, 2017

There"s Still Life in Spark

Spark Therapeutics shares have sold off sharply—but there’s more to the biotech than one treatment......»»

Category: topSource: barronsDec 16th, 2017

Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment

Shares of biotech Stemline Therapeutics Inc. jumped 4% premarket Wednesday, after the company said a trial of a treatment for acute myeloid leukemia met its main goal. Stemline said d.....»»

Category: topSource: marketwatchDec 13th, 2017

Spark Therapeutics shares slide more than 40% after hemophilia data disappoint

Shares of gene therapy biotech Spark Therapeutics Inc. tumbled more than 40% in early trade Monday, after it reported data from trials of a hemophilia treatment that analysts said look less competitive than a rival product from BioMarin Pharma.....»»

Category: topSource: marketwatchDec 11th, 2017

All The Sell-Side Responses To Spark Therapeutics" Strong AdCom Meeting On Luxturna

On Thursday afternoon, and FDA advisory panel recommended approval of Spark Therapeutics Inc (NASDAQ: ONCE)’s Luxturna treatment for inherited blindness. Latest Ratings for ONCE.....»»

Category: blogSource: benzingaOct 13th, 2017

Spark Therapeutics shares halted as FDA advisory committee reviews gene therapy

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchOct 12th, 2017

Spark Therapeutics applies to market investigational therapy in Europe

The gene therapy company that spun out of Children's Hospital of Philadelphia is moving forward with a regulatory review of its treatment of an inherited disease that leads to blindness in Europe – laying the groundwork for the investigational therapy .....»»

Category: topSource: bizjournalsJul 31st, 2017

Menlo Therapeutics" stock plunges over 50% after disappointing trial results

Shares of Menlo Therapeutics Inc. lost more than half their value in premarket trade Monday, after the biopharmaceutical company's skin condition treatment failed to meet its primary or key secondary efficacy endpoints. The phase 2 trial showed no stat.....»»

Category: topSource: marketwatchApr 9th, 2018

Ionic Pharmaceuticals shares jump 3% premarket on news of license deal with AstraZeneca

Ionis Pharmaceuticals Inc. shares rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver. Ionis said it will receive .....»»

Category: topSource: marketwatchApr 9th, 2018

AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial

Shares of AbbVie Inc. jumped 2.2% in premarket trade Monday, after the company reported positive results in a late-stage trial of a treatment for rheumatoid arthritis. AbbVie said the phase 3 trial of upadacitinib met its primary endpoints. Upadaciti.....»»

Category: topSource: marketwatchApr 9th, 2018

Incyte"s stock set for selloff, Merck shares drop after disappointing study results of melanoma treatment

Incyte Corp. and Merck & Co. Inc. said an external data monitoring committee (eDMC) determined that results from a phas.....»»

Category: topSource: marketwatchApr 6th, 2018

Proteostasis shares surge 12% on FDA "fast track" designation for cystic fibrosis treatment

Proteostasis Therapeutics Inc. shares rose 12.4% in premarket trade Wednesday after the company's combination treatment for cystic fibrosis received a "fast track" designation from the Fo.....»»

Category: topSource: marketwatchApr 4th, 2018

Adaptimmune Therapeutics shares soar 26% on news of positive early signs for cancer treatment

Shares of Adaptimmune Therapeutics Plc surged 26% Thursday, after the company reported positive early results for a can.....»»

Category: topSource: marketwatchMar 15th, 2018

Alexion shares jump 11% premarket on news of positive trial of treatment for rare blood disorder

Shares of biotech Alexion Pharmaceuticals Inc. soared 11% in premarket trade Thursday, a.....»»

Category: topSource: marketwatchMar 15th, 2018

Sarepta Therapeutics plans NDA of Duchenne MD treatment by year end

Shares of Sarepta Therapeutics Inc. surged 4.9% in premarket trade Monday, after the biopharmaceutical company said it planned to submit a New Drug Application (NDA) for its Duchenne muscular dystrophy treatmen.....»»

Category: topSource: marketwatchMar 12th, 2018

Vascular Biogenics" stock plummets after brain cancer treatment trial fails

Shares of Israel-based Vascular Biogenics Ltd., which is operating as VBL Therapeutics, plummeted 63% toward a record low in premarket tr.....»»

Category: topSource: marketwatchMar 8th, 2018

UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4%

Esperion Thera.....»»

Category: topSource: marketwatchMar 7th, 2018